The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2022 | Mosunetuzumab monotherapy in R/R FL
Dima El-Sharkawi, MBBS, MA, PhD, MRCP, FRCPath, The Royal Marsden NHS Foundation Trust, Sutton, UK, shares the results of the dose expansion phase of a study evaluating mosunetuzumab monotherapy in patients with relapsed/refractory (R/R) follicular lymphoma (FL) who have received a median of three lines of prior therapy. The study reported an overall response rate (ORR) of 80%, a complete response (CR) rate of 60%, and a progression-free survival (PFS) of 18 months. The drug appeared to be well tolerated, with low rates of grade 1-2 cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
Disclosures
Honoraria: Abbvie; AstraZeneca; Gilead, Janssen; Roche; Takeda
Conference/ Travel support: Abbvie; Novartis
Ad boards: Abbvie; ASTEX; AstraZeneca; Beigene; Janssen; Kyowa Kirin
